A randomized, double-blind, placebo-controlled, parallel-group, 52week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CEREN-1)

Principal Investigator

Ali Qureishi

Contact us

Email: crndirectdeliveryteam@ouh.nhs.uk

IRAS number

1010939